drugset
drugset / Trial / NCT02182284

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

NCT02182284 ↗

Phase 1 Completed 34 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of this study was to establish the relative bioavailability of a new soft gelatin capsule (SGC) formulation of BI 201335 NA compared to the current solution formulation (powder in bottle, PIB) for two doses (40 mg, 240 mg) in a parallel, two-way cross-over study design.

Timeline

Start
2008-01
Primary completion
2008-02
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Faldaprevir Small molecule 40 mg —
Subject Faldaprevir Small molecule 240 mg —

Indications

No indication recorded.